Zynex, Inc. (NASDAQ:ZYXI) CEO Sells $17,540.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $8.77, for a total value of $17,540.00. Following the sale, the chief executive officer now directly owns 14,611,662 shares of the company’s stock, valued at $128,144,275.74. This represents a 0.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 13th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.37, for a total transaction of $16,740.00.
• On Monday, November 11th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $9.09, for a total transaction of $18,180.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.82, for a total value of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total value of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Trading Down 3.6 %

Shares of ZYXI opened at $7.80 on Friday. The company’s fifty day simple moving average is $8.23 and its 200-day simple moving average is $8.88. The company has a market cap of $248.43 million, a P/E ratio of 52.00 and a beta of 0.53. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same period in the prior year, the company posted $0.10 EPS. The firm’s revenue for the quarter was up .1% on a year-over-year basis. As a group, analysts expect that Zynex, Inc. will post 0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

ZYXI has been the topic of a number of research analyst reports. Royal Bank of Canada decreased their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright upped their price objective on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, October 25th.

Institutional Investors Weigh In On Zynex

Institutional investors and hedge funds have recently modified their holdings of the business. State Board of Administration of Florida Retirement System purchased a new stake in Zynex in the first quarter worth $137,000. Vanguard Group Inc. grew its holdings in shares of Zynex by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock worth $14,684,000 after purchasing an additional 6,097 shares during the last quarter. BOKF NA purchased a new position in Zynex in the 1st quarter worth about $246,000. Hancock Whitney Corp lifted its holdings in Zynex by 24.9% during the 1st quarter. Hancock Whitney Corp now owns 32,903 shares of the company’s stock valued at $407,000 after buying an additional 6,566 shares in the last quarter. Finally, Platte River Wealth Advisors LLC lifted its holdings in Zynex by 200.0% during the 2nd quarter. Platte River Wealth Advisors LLC now owns 30,000 shares of the company’s stock valued at $280,000 after buying an additional 20,000 shares in the last quarter. 29.68% of the stock is owned by institutional investors.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.